GvHD Could Yield To MaaT Pharma's Microbiome-Based Ecosystem Therapies
Phase III Studies Planned
MaaT Pharma’s replacement bacterial ecosystem for the gastro-intestinal tract, MaaT103, has shown promise in top-line data from a Phase II study in patients with refractory aGvHD, energizing the microbiome field.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Competing with several other firms to bring the first microbiome-derived therapy to market, Seres says the magnitude of its Phase III efficacy compared to placebo may enough for registrational filing.
Germany’s Boehringer Ingelheim highlighted its clinical-stage research efforts in neuropsychiatry and COVID-19 when describing its first half financial results as solid, despite the continuing impact of the pandemic.